Development of methods for reducing venous pain caused by dacarbazine

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08117
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Setsunan University
• Principal Investigator: KOHNO Takeyuki 摂南大学, 薬学部, 教授 (50178224)
• Co-Investigator(Renkei-kenkyūsha): TSUJI Takumi 摂南大学, 薬学部, 准教授 (90454652) ; YOSHIDA Yuya 摂南大学, 薬学部, 講師 (50581435) ; BANNO Rie 摂南大学, 薬学部, 助教 (90736844)
• Research Collaborator: MIKAMI Tadashi ; OHTSUBO Tatsuya
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: ダカルバジン / Diazo-IC / 血管痛 / ザルトプロフェン

Outline of Final Research Achievements

Venous pain caused by dacarbazine (DTIC), the anticancer drug, is due to its photodegradation product 5-diazoimidazole-4-carboxamide (Diazo-IC). In this study, we indicated that the methods for reducing degradation of DTIC to Diazo-IC, namely not only shielding against light but also veen F injection decreased the production of Diazo-IC compared with the normal saline and 5％ glucose solution and elucidated that premedication drugs such as zaltoprofen and homochlorcyclizine hydrochlride significantly decreased the expression of pain behavior in the DTIC-treated mice. Furthermore, we found that shortening the injection preparation time tended to decrease the local venous pain expression due to DTIC.

Free Research Field

免疫学，病態生化学